Abstract:BackgroundTislelizumab, an anti-programmed cell death protein-1 monoclonal antibody, demonstrated clinical activity and was well tolerated in patients with previously treated advanced HCC in the open-label, multicenter, Phase 2 RATIONALE-208 study (NCT03419897). We report exploratory analysis of the association of gene expression profiles (GEPs) with response to tislelizumab in patients with previously treated advanced HCC.MethodsEligible patients who had received ≥1 prior line of systemic therapy for advanced HCC received tislelizumab (200 mg) intravenously once every 3 weeks and tumor response was evaluated per RECIST v.1.1. Baseline tumor sampling was optional and GEP analysis was performed using HTG EdgeSeq Precision Immuno-Oncology panel in 138 tumor samples (fresh tumor, n=6; archival tumor, n=132). Signature scores were calculated using Gene Set Variation Analysis package with publicly available gene signatures (GS). GS or genes differentially expressed between responders and non-responders (NRs) were determined using Wilcoxon rank-sum test and modified t-test with limma. Distributions of overall survival (OS) and progression-free survival (PFS) for GS subgroups (high vs low) were estimated by Kaplan-Meier method. Hierarchical clustering of NRs was achieved using 1-Pearson’s correlation and average linkage. All statistical analysis results are post-hoc exploratory and thereby p values are descriptive.Results249 patients were enrolled and received ≥1 dose of tislelizumab; 138 patients had evaluable GEP data, of which 132 patients had evaluable GEP and tumor response data. GEP analysis demonstrated that CD4 T cell, CD8 T cell, cytotoxic T lymphocyte and major histocompatibility complex class I signatures were enriched in responders, and cancer-associated fibroblasts, angiogenesis and hypoxia signatures were enriched in NRs (figure 1). CD8B_PDCD1_9, a novel GS identified, comprises 9 genes highly expressed in responders: CD8B, CXCL13, KLRD1, NKG7, HLA-A, HLA-G, LAG3, PDCD1 and KREMEN1. Higher objective response rate (ORR; p<0.0001, by Fisher’s exact test) and longer PFS (p=0.005, by log rank test) were observed in patients with high vs low CD8B_PDCD1_9 score (ORR: 26% vs 3%; median PFS: 2.8 months vs 1.8 months). To explore the heterogeneity of molecular features in NRs, NRs were clustered into 3 subgroups using a series of tumor-immune GS. OS and PFS for the 3 NR subgroups with distinct GS are summarized in table 1.Abstact 360 Figure 1Correlation between GS and ORR in patients with previously treated advanced HCC treated with tislelizumab monotherapyAbstact 360 Table 1OS and PFS of NR subgroupsCl, confidence interval; NE, not evaluable; GS, gene signature; NR, non-responder; OS, overall survival; PFS, progression-free survivalConclusionsThis exploratory analysis identified distinct GS associated with tumor response and resistance to tislelizumab monotherapy in patients with previously treated advanced HCC and increases our understanding of the tumor microenvironment. Further GEP analyses will be undertaken in an on-going Phase 3 study (NCT03412773).AcknowledgementsThis study is sponsored by BeiGene Ltd. Medical writing support for the development of this abstract, under direction of the authors, was provided by Claire White, PhD, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene Ltd.Trial RegistrationNCT03419897Ethics ApprovalThis study was conducted according to the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, the principles of informed consent and the requirements of the public registration of clinical trials. Written informed consent was obtained from each patient prior to screening. The protocol was approved by the institutional ethics committee and was monitored by a safety monitoring committee.

Supplementary Figure 6 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma

Establishment and Validation of a Novel Disulfidptosis-Related Immune Checkpoint Gene Signature in Clear Cell Renal Cell Carcinoma.

Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma

Prognostic Prediction and Immunotherapy Response Analysis of the Fatty Acid Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma

Chromatin Helicase CHD6 Establishes Pro-inflammatory Enhancers and is a Synthetic Lethal Target in FH-Deficient Renal Cell Carcinoma.

Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma

TKI Resistant-Based Prognostic Immune Related Gene Signature in LUAD, in Which FSCN1 Contributes to Tumor Progression.

360 Tumor-immune Signatures Associated with Response or Resistance to Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)

Single-cell transcriptomics reveals a low CD8 + T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma

MP18-04 TUMOR-INFILTRATING TNFRSF9+ CD8 T CELLS IN RENAL CELL CARCINOMA HOLD BOTH EXHAUSTION AND EFFECTOR PHENOTYPE AND RESPONSE BETTER TO IMMUNOTHERAPY

Identification and Validation of a Prognostic Signature Based on Fibroblast Immune-related Genes to Predict the Prognosis and Therapeutic Response of renal clear cell carcinoma by Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data

Abstract 3457: Distinct signatures of tumor-associated macrophage subpopulations predict survival in renal cell carcinoma

An Immune-Related Signature Predicted Survival in Patients With Kidney Papillary Cell Carcinoma

Characterization of FOLH1 Expression in Renal Cell Carcinoma

FHL2 Determines Poor Outcomes and Responsiveness of Immunotherapy Plus Tyrosine Kinase Inhibition in Metastatic Renal Cell Carcinoma

Identification of a Six-Gene Prognostic Signature Characterized by Tumor Microenvironment Immune Profiles in Clear Cell Renal Cell Carcinoma

Single-cell epigenetic profiling reveals an interferon response-high program associated with deficiency in kidney cancer

As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner

Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer

Identification and Validation of an 8-Gene Expression Signature for Predicting High-Fuhrman Grade Renal Cell Carcinoma.

Immune signature of tumor infiltrating immune cells in renal cancer